Hana Biosciences (HNAB) Completes rALLy Phase 2 Enrollment for Marqibo
Hana Biosciences (OTCBB: HNAB) today announced that it has completed enrollment of its pivotal Phase 2 rALLy clinical trial for Marqibo (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse, enrolling a total of 65 patients. The Company chose to exceed its enrollment target of 56 subjects, which was reached in August 2009, to collect a more robust pharmacokinetic data set in the adult ALL patient population. Patients have been enrolled and dosed at 22 sites in the United States, Canada, Germany, and Israel.
In June, during the 44th Annual American Society of Clinical Oncology (ASCO) Meeting, Hana announced preliminary data from the Phase 2 rALLy clinical trial, which showed encouraging anti-leukemic activity in a relapsed/refractory adult ALL patient population, enabling several patients to receive a potentially curative stem cell transplant. Data presented at ASCO also showed encouraging preliminary response duration and overall survival data, as well as a predictable safety profile with no unexpected toxicity.
The primary objective of the pivotal Phase 2 rALLy clinical trial is to assess the efficacy of single-agent, weekly Marqibo (2.25 mg/m2) with dosing based on actual body surface area without the dose capping applied to standard vincristine. Secondary objectives include evaluation of safety, response duration, and survival. The study population is defined as Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
